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Abstract 
Background: The number of Mesenchymal Stem/Stromal Cells (MSCs) in the human bone marrow (BM) is small 
compared to other cell types. BM aspirate concentration (BMAC) may be used to increase numbers of MSCs, but the 
composition of MSC subpopulations and growth factors after processing are unknown. The purpose of this study 
was to assess the enrichment of stem/progenitor cells and growth factors in BM aspirate by two different commercial 
concentration devices versus standard BM aspiration.
Methods: 120 mL of BM was aspirated from the iliac crest of 10 male donors. Each sample was processed simulta-
neously by either Emcyte  GenesisCS® (Emcyte) or Harvest SmartPReP2 BMAC (Harvest) devices and compared to 
untreated BM aspirate. Samples were analyzed with multicolor flow cytometry for cellular viability and expression 
of stem/progenitor cells markers. Stem/progenitor cell content was verified by quantification of colony forming 
unit-fibroblasts (CFU-F). Platelet, red blood cell and total nucleated cell (TNC) content were determined using an 
automated hematology analyzer. Growth factors contents were analyzed with protein quantification assays. Statistical 
analyses were performed by ANOVA analysis of variance followed by Tukey’s multiple comparison test or Wilcoxon 
matched-pairs signed rank test with p < 0.05 for significance.
Results: Cell viability after processing was approximately 90% in all groups. Compared to control, both devices 
significantly enriched TNCs and platelets, as well as the CD45−CD73+ and CD45−CD73+CD90+ cell popu-
lations. Further, Harvest significantly concentrated CD45−CD10+, CD45−CD29+, CD45−CD90+, CD45−
CD105+, CD45−CD119+ cells, and CD45dimCD90+CD271+ MSCs, whereas Emcyte significantly enriched 
CD45dimCD44+CD271+ MSCs. BM concentration also increased the numbers of CFU-F, platelet-derived growth 
factor, vascular endothelial growth factor, macrophage colony-stimulating factor, interleukin-1b, VCAM-1 and total 
protein. Neither system concentrated red blood cells, hematopoietic stem cells or bone morphogenetic proteins.
Conclusion: This data could contribute to the development of BMAC quality control assays as both BMAC systems 
concentrated platelets, growth factors and non-hematopoietic stem cell subpopulations with distinct phenotypes 
without loss of cell viability when compared to unprocessed BM.
Keywords: Bone marrow aspirate concentrate, Bone marrow aspiration, BMAC, Growth factors, Mesenchymal stem 
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Background
Human BM aspirate contains Mesenchymal Stem/Stro-
mal Cells (MSCs) [1, 2], but the number of MSCs are 
low, estimated at 0.01–0.02% of the total cell volume [3]. 
Therefore, processing BM by BMAC may be clinically 
beneficial to increase the concentration of MSCs [4–6]. 
In recent years, the use of bone marrow aspirate con-
centrate (BMAC) has become an increasingly popular 
method of augmenting bone [7, 8] and cartilage regen-
eration [1] in orthopaedic surgery. BMAC is obtained 
through density gradient centrifugation of bone mar-
row (BM) typically aspirated from the iliac crest. It is 
currently approved by the United States Food and Drug 
Administration for clinical use as a means of acquiring 
progenitor cells and growth factors to promote healing in 
the orthopaedic patient [2].
A combination of different markers has been suggested 
to characterize MSCs present within BM, but especially 
in  vitro expanded MSCs, e.g. CD45−, CD90+, CD73+, 
and CD271+ [5]. However, the exact phenotype of MSCs 
has not been agreed on yet due to the intrinsic hetero-
geneity of BM being comprised of different cell subsets 
and likely variable differentiation stages of the MSCs. 
Previous studies have reported considerable donor–
donor variation that increases the heterogeneity of MSC 
phenotypes [5]. Consequently, clinical trials employing 
MSCs are inconsistent, hampering their broad transla-
tion into clinical practice. It is imperative to compare 
BMAC produced by commercially available systems to 
better understand its therapeutic potential and to even-
tually establish a correlation between the progenitor cell 
composition, the concentration of biologic factors and 
clinical outcome.
The purpose of this study is to analyze and compare 
progenitor cell composition and growth factors in BMAC 
prepared from single donors and processed concurrently 
by two commercially available systems versus unpro-
cessed marrow aspiration. We hypothesized that the 
BMAC systems will concentrate progenitor cell popu-
lations when compared to unprocessed BM without a 
meaningful loss of cell viability.
Methods
Bone marrow aspirate collection and processing
After ethical approval and informed consent was 
obtained, 120  mL (60  mL per iliac crest) of bone mar-
row aspirate (BMA) was harvested from the anterior 
iliac crests of 10 male adult human donors (age range 
28–35 years) using multiple puncture sites. Four mL of 
aspirate was withdrawn into a 60 mL syringe at each site 
into a syringe containing 1000 U/mL of heparin (Sigma-
Aldrich, St. Louis, MO, USA). This process was repeated 
after the side-port Jamshidi needle was rotated 180 
degrees and was withdrawn 1 cm until a total volume of 
60 mL BM was obtained. This process was then repeated 
using the contralateral iliac crest and then consolidated 
into one BM sample of 120 mL per donor. Donors with 
conditions that could potentially compromise BM qual-
ity, including history of hematologic malignancy, current 
chemotherapy, BM suppressive and anti-platelet medi-
cations, previous BMA, or acute illness where excluded 
from this study.
Under sterile laboratory conditions, the BMA was agi-
tated with a shaker and was alloquated on a rotating basis 
into the two experimental groups, which totaled 55  mL 
aliquots for each BMAC system, i.e. Emcyte  GenesisCS® 
(Fort Myers, FL, USA) and Harvest SmartPReP2 
 BMAC®  (Lakewood, CO, USA), and processed per the 
manufacturer’s instructions.
Company representatives were present ensuring proper 
protocols were followed. 10  mL of BMA was randomly 
allocated into the unprocessed control group, and served 
as internal control for the respective donor/experiment. 
Each system was adjusted to produce 7  mL of BMAC. 
All samples were re-suspended in Alpha MEM media 
(Lonza, Basel, Switzerland) and 1% Antibiotic–Antimy-
cotic (Gibco, Grand Island, NY, USA) (7 mL BMAC in a 
total volume of 30 mL; 10 mL BMA in a total volume of 
15 mL).
Quantification of blood cells
Red blood cells (RBCs), platelets and total nucleated cells 
(TNCs) were quantified in each group using the Sys-
mex XT-1800i Automated Hematology Analyzer (Kobe, 
Japan).
Flow cytometry analyses
Flow cytometry was performed to assess the impact of 
BMAC on important MSC populations [6–8]. Before 
flow cytometry analysis, BMA cells were washed with 
PBS and mononuclear cells were separated using Biocoll 
Separating Solution (Biochrom GmbH, Berlin, Germany) 
by centrifugation at + 4 °C, without brake for 25 min. at 
400×g. To detach cells possibly adherent to the tube, they 
were incubated with 0.25% trypsin/EDTA (Gibco) for 
5  min. at + 37  °C. After trypsin inactivation with phos-
phate buffered saline (PBS–DPBS; Gibco) + 10% fetal calf 
serum (PAN-Biotech GmbH, Aidenbach, Germany) they 
were added to the BMA samples prior to Biocoll sepa-
ration. RBC lysis was performed by incubating the cells 
for 25 min. at + 37 °C with Red Blood Cell Lysing Buffer 
(Sigma, Steinheim, Germany). After an additional wash-
ing step with PBS, multicolor staining was performed at 
the manufacturer’s recommended concentrations of spe-
cific primary antibodies or isotype controls. Non-labeled 
primary antibodies were detected by secondary antibody, 
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goat-anti mouse-PE after incubation on ice for 20  min 
(Table  1). Via-Probe™-7AAD solution (BD Biosciences 
San Diego, CA, USA) was added to determine cell viabil-
ity. To identify progenitor cells and MSC subpopulations 
we applied combinations of markers that are commonly 
accepted as being either present or absent on MSCs 
(“mandatory markers”). In addition, as a novel approach, 
we tested the co-expression of markers that have been 
described to identify MSC subpopulations (“optional 
markers”) (Table  1). Flow cytometry was performed 
using the LSRFortessa™ cell analyzer (BD Biosciences) 
and data were analyzed using FACSDiva™ software (BD 
Biosciences). In order to detect rare stem cell subpopula-
tions for each sample 1 × 106 events were analyzed. For 
gating strategy see Additional file 1: Figure S1.
Colony‑forming unit‑fibroblasts (CFU‑F) Assay
To functionally assess non-hematopoietic stem/progeni-
tor cell content CFU-F assays were performed. BMAC 
and control cell suspensions were applied to Biocoll 
Separating Solution (Biochrom GmbH) and separated by 
density gradient centrifugation without break at 400×g 
for 20  min. Mononuclear cells were washed twice with 
PBS followed by centrifugation at 400×g for 5 min. The 
cell pellets were re-suspended in Alpha MEM (Lonza) 
supplemented with 10% human platelet lysate (German 
Red Cross Blood Service Baden-Württemberg—Hes-
sen gGmbH, Frankfurt, Germany), 1x  Gibco® Antibi-
otic–Antimycotic (Life Technologies, NY, USA), 2 IU/mL 
Heparin-Natrium 5000 (Ratiopharm, Ulm, Germany) 
and seeded at a density of 5 × 105 cells per well into 6 well 
plates (Thermo Fischer Scientific Nunc A/S, Roskilde, 
Denmark). Cells were incubated at 37  °C with 5%  CO2. 
The media was changed every 3  days, and the cultures 
were evaluated after 10  days microscopically. CFU-F 
were defined as a minimum of 50 cells per CFU-F. Colo-
nies were counted in replicates and subsequently com-
pared as mean data for each condition and donor.
Enzyme‑linked immunosorbent assay (ELISA)
For quantification of growth factors and protein con-
tent in the cells, mononuclear cells from control and 
both BMAC groups, after Biocoll separation, were 
lysed (3 freeze/thaw cycles), and the lysate supernatants 
Table 1 Antibodies used for flow cytometry and rationale for marker selection
Rationale for analysis
Specific antibody Fluoro‑chrome Clone Manufacturer Mandatory
Marker presence/absence 
identify MSCs (include “ISCT 
markers”)
Optional
Marker presence refine MSC 
subpopulations phenotypes
Anti-human CD29 PE MAR4 BD Biosciences Present in vitro (ISCT consen-
sus) [9]
Anti-human CD44 APC DB105 Miltenyi Biotec
(Bergisch-Gladbach, Germany)
Present in vitro [5]
Anti-human CD73 APC AD2 Biolegend
(San Diego, CA, USA)
Present in vitro (ISCT consen-
sus) and in vivo [4, 5, 28]
Anti-human CD90 APC 5E10 BD Biosciences Present in vitro (ISCT consen-
sus) and in vivo [5, 6, 28]Anti-human CD90 PE 5E10 BD Biosciences
Anti-human CD105 purified 266 BD Bioscience Present in vitro (ISCT consen-
sus) [28]
Anti-human CD34 FITC 581 Molecular Probes Life Tech-
nologies
(Carlsbad, CA, USA)
Absent in vitro (ISCT consen-
sus) [28]; identifies HSC
Anti-human CD45 FITC HI30 BD Biosciences Absent in vitro (ISCT consen-
sus) [28]; identifies WBC and 
HSC
Anti-human CD10 PE HI10A BD Biosciences In vitro and in vivo [4, 5]
Anti-human CD119 PE GIR-208 BD Biosciences In vitro [5]
Anti-human CD271 PE ME20.4-1.H4 Miltenyi Biotec In vitro and in vivo [4–6]
Anti-human GD2 purified 14.G2A BD Bioscience In vitro and in vivo [4, 5]
Goat anti-mouse PE Polyclonal BD Bioscience
IgG1 FITC MOPC-21 BD Biosciences
IgG1 PE MOPC-21 BD Biosciences
IgG1 APC MOPC-21 BD Biosciences
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were then analyzed using the Quantibody-Array QAH-
BMA-1000-2 (RayBiotech, Norcross, GA, USA) and 
ELISA assays (Peprotech, Hamburg, Germany) following 
the manufacturer’s instructions.
Statistical analyses
In order to account for donor-to-donor variability and 
to achieve data comparability between flow cytometry 
experiments, the percentages of viable antigen(s) posi-
tive/negative cells of the BMAC groups were divided by 
the percentages of the corresponding controls for each 
experiment. The calculated ratios represent the specific 
fold changes for each tested marker, or marker combina-
tion, of BMAC compared to the respective internal con-
trol (single donor).
To get an estimate about the respective cell numbers, 
percentages of subpopulations related to the recorded 
viable cell counts are presented in Additional file  2: 
Table S1.
The statistical analyses were performed by ANOVA 
analysis of variance followed by Tukey’s multiple com-
parison test, or Wilcoxon matched-pairs signed rank test 
using GraphPad Prism (La Jolla, CA, USA). Differences 
were considered significant when p < 0.05. Presented data 
for blood cell counts, CFU-F and growth factors were cal-
culated of original non-diluted samples based on analyses 
of diluted samples considering respective sample dilu-
tions (both BMAC: 4.29×, controls: 1.50×) to quantify 
and compare actual contents.
Results
Mean cell viability after processing was similar for unpro-
cessed controls (91.57%), Harvest (89.71%) and Emcyte 
(92.29%) systems (p > 0.05) (Fig. 1).
Concentrations of TNCs were significantly higher in 
both BMAC groups compared to controls indicating an 
approx. tenfold concentration (Harvest: 235.11 × 103/
µL, p = 0.0472; Emcyte: 265.28 × 103/µL, p = 0.0307; 
control: 24.49 × 103/µL) (Fig.  2a). Both BMAC groups 
concentrated platelets (Harvest: 627.77 × 103/µL, 
p = 0.0205; Emcyte: 802.23 × 103/µL, p = 0.0075; control: 
100 × 103/µL) (Fig. 2b) but depleted red blood cells (Har-
vest: 2.36 × 106/µL, p = 0.0016; Emcyte: 1.57 × 106/µL, 
p = 0.0008; control: 5.99 × 106/µL) (Fig. 2c).
Overall, hematopoietic cell (CD45+) content was 
lower in both BMAC groups compared to the unpro-
cessed control (Harvest: 0.86 fold vs control, p = 0.5781; 
Emcyte: 0.83 fold vs control, p = 0.375) (Fig.  3a). Spe-
cifically, CD45+29+ cells were depleted (Harvest: 0.99 
fold vs control, p = 0.9375; Emcyte: 0.75 fold vs control, 
p = 0.0469) (Fig.  3b). Interestingly, the content of dis-
tinct CD45+ cell populations was enriched after BM 
aspirate concentration, i.e. CD45+73+ (Harvest: 2.71 
fold vs control, p = 0.0313; Emcyte: 2.13 vs control, 
p = 0.1563), CD45+90+ (Harvest: 2.61 fold vs con-
trol, p = 0.0781; Emcyte: 2.74 vs control, p = 0.0469), 
Fig. 1 Cell viability in both BMAC groups and controls. N = 10 
donors; ANOVA analysis of variance; error bars: standard error of 
means (SEM)
Fig. 2 Blood cell counts in both BMAC groups and controls. N = 3 donors; ANOVA analysis of variance; error bars: SEM
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and CD45+73+CD90+ (Harvest: 3.51 fold vs control, 
p = 0.0313; Emcyte: 2.11 vs control, p = 0.0781) cells 
(Fig. 3c). Notably, both BMAC groups did not concen-
trate CD34+ hematopoietic progenitor cells (Harvest: 
0.809 fold vs control, p = 0.71; Emcyte: 1.088 vs control, 
p = 0.93) (Fig. 3d).
In contrast, the BMAC systems enriched distinct sets 
of CD45− and CD45dim non-hematopoietic progenitor 
subpopulations. Specifically, both devices significantly 
enriched CD45−CD73+ (Harvest: 9.2 fold vs control, 
p = 0.0313; Emcyte: 11.9 fold vs control, p = 0.0469) and 
CD45−CD73+CD90+ (Harvest: 12.9 fold vs control, 
p = 0.0156; Emcyte: 7.8 vs control, p = 0.0469) cells.
Moreover, Harvest contained significantly more 
CD45−CD10+ (3.6 fold vs control, p = 0.0156), 
CD45−CD29+ (1.6 fold vs control, p = 0.0156), 
CD45−CD90+ (14.8 fold vs control, p = 0.0156), 
CD45−CD105+ (8.8 fold vs control, p = 0.0469), 
Fig. 3 Quantification of hematopoietic (CD45+) cells in both BMAC groups versus controls. N = 7 donors (except for CD34+ [3 donors]); Wilcoxon 
matched-pairs signed rank test; error bars: SEM
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CD45−CD119+ (4.8 fold vs control, p = 0.0313) 
cells, and CD45dimCD90+CD271+ (4.2 fold vs con-
trol, p = 0.0469) MSCs. Emcyte significantly enriched 
CD45dimCD44+CD271+ (4.9 fold vs control, 
p = 0.0313) MSCs (Fig. 4).
In addition to stem/progenitor cell phenotype analy-
ses by flow cytometry, the non-hematopoietic stem cell 
content was assessed by CFU-F assay. We observed for 
both BMAC a donor-depending non-hematopoietic 
progenitor cells enrichment between 4.4 and 41.2 fold 
(Table 2).
ELISA growth factor analysis of the cell lysates illus-
trated considerable variability between donors. Both 
Harvest and Emcyte concentrated platelet-derived 
growth factor (PDGF)-BB, vascular endothelial growth 
factor (VEGF), macrophage colony-stimulating factor 
(M-CSF), interleukin (IL)-1b, VCAM-1, osteoactivin 
and total protein compared to controls (Fig.  5). BMPs 
− 2, − 4, − 6, − 7 and − 9 were not detectable in most 
samples.
Discussion
Both commercial BMAC systems significantly concen-
trated MSC populations, platelets and growth factors, 
but not hematopoietic progenitor cells, compared to 
untreated marrow aspirate from single donors. This is an 
important finding as the number of MSCs in BM is small, 
estimated at 0.01–0.02%, compared to other cell types. 
Our data corroborate other studies showing BMAC sys-
tems are effective in concentrating MSCs [9, 10].
Fig. 4 Comparison of MSC subpopulations (CD45−/dim) detected in both BMAC groups versus controls; N = 7 donors (except for CD45−
CD73+ CD271 [4 donors], CD45−CD90+ CD271 [5 donors], CD45−CD44+ CD271 [5 donors], and CD45dimCD44+ CD271 [6 donors]); Wilcoxon 
matched-pairs signed rank test; error bars: SEM
Table 2 Non-hematopoietic progenitor cells content 
in both BMAC groups and controls assessed by CFU-F assay
CFU-F: CFU-F total calculated per mL of original, non-diluted sample; 
enrichment factor: BMAC CFU-F compared to control CFU-F; data are presented 
as means per donor (N = 3)
Control Harvest Emcyte




Donor 1 127.08 407.98 4.43 1970.65 21.15
Donor 2 88.23 1758.86 19.93 3638.99 41.24
Donor 3 393.32 8194.07 22.47 9766.19 26.44
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Despite enrichment of biologic factors, the question 
remains as to whether higher MSC content in BMAC 
leads to improved clinical efficacy. Hernigou et  al. [11] 
illustrated that concentrating BMA could increase 
the progenitor cell population from 612 ± 134 pro-
genitor cells/cm3 before concentration to an average 
of 2579 ± 1121 progenitor cells/cm3 after processing. 
In their study of patients with atrophic non-unions of 
the tibia who received percutaneous BMAC injections, 
the volume of mineralization of the fracture callus at 
4 months was directly related to the number of progeni-
tor cells in the original injection, providing evidence that 
the efficacy of BM aspirations for fracture healing can be 
enhanced with BMAC [3]. Bony union was achieved in 
88% of their patients at 4  months following the proce-
dure, and they concluded that BMAC was effective as a 
single stage procedure to treat atrophic tibial non-unions 
without the risk of complications related to in  vitro 
expansion.
Hernigou et al. [3] also illustrated that fracture healing 
efficiency was associated with higher CFU-F numbers, a 
functional assay correlated to the clone forming capac-
ity of the cells, in BMAC. Although our study did show 
an increase in CFU-Fs in both BMAC groups, the previ-
ous literature suggests that CFU-F quantification alone 
might not be sufficient to assess BMAC’s therapeutic 
potential [12]. Moreover, the CFU-F assay cannot pro-
vide timely results as it requires several days ex vivo cul-
ture time.
BMAC may also promote tissue healing by deliver-
ing platelets as well as non-cellular growth factors [2, 
5, 11, 13–15]. Perhaps one of the more notable findings 
in this study is that BMAC increases concentrations of 
PDGF-BB and VEGF in mononuclear cells. PDGF-BB is 
a potent recruiter of cells crucial to musculoskeletal tis-
sue repair, including MSCs, osteogenic cells and teno-
cytes. Additionally, it up regulates angiogenesis thereby 
initiating a cascade of bone and soft tissue repair mech-
anisms in the presence of injury [16]. VEGF belongs 
to a subset of the PGDF family and serves as a potent 
initiator of angiogenesis in response to injury [17]. 
As we analyzed the growth factors from the lysates of 
the mononuclear cell fraction we hypothesize that the 
higher growth factors concentrations we observed in 
BMAC were related to the higher numbers of progeni-
tor cells rather than platelets contents. Yet, it may be 
reasonable to assume that both cell types contribute 
synergistically as they have been shown to carry such 
proteins [18].
Both BMAC technologies concentrated TNCs but did 
not increase the overall content of hematopoietic cells 
Fig. 5 Quantification of growth factors in MNC cell lysates of both BMAC groups and controls. N = 3 donors; boxes highlight factors enriched by 
BMAC compared to controls. Points represent mean values for each donor
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(CD45+). BMAC significantly reduced (CD45+CD29+) 
but also enriched (CD45+73+, CD45+90+, 
CD45+73+CD90+) distinct subsets expressing mark-
ers that have been detected on a great variety of immune 
cells such as T cells, B cells, dendritic cells, and mono-
cytes as well as on hematopoietic progenitor cells [19, 
20].
Yet, to date, the effects of immune cell subset depletion 
or concentration by BMAC on tissue regeneration remains 
unclear. Additionally, the clinical relevance of specific 
significantly enriched CD45− (progenitor) subpopula-
tions CD45−CD10+, CD45−CD29+, CD45−CD73+, 
CD45−CD90+, CD45−CD105+, CD45−CD119+, 
CD45−CD73+CD90+, CD45dimCD44+CD271+, and 
CD45dimCD90+CD271+ is unknown, especially with 
regards to augmenting bone and/or cartilage regeneration. 
CD45−CD10+, CD45−CD29+, CD45−CD119+ and 
CD45−CD73+CD90+ phenotypes are part of both 
endothelial cell and MSC marker profiles [5], but their con-
crete relevance to regenerative medicine is also unknown. 
However, the increase of CFU-F supports the MSC enrich-
ment in both BMAC groups, and the marker combination 
CD45dimCD90+CD271+ specifically characterizes highly 
clonogenic multipotent MSCs with significant osteogenic 
differentiation capacity [21, 22]. This specific subpopula-
tion was concentrated in BMAC, providing further proof 
of concept for its clinical use. Yet, it has to be noted that 
the observed increase of CD45dimCD90+CD271+ events 
detected by flow cytometry reflects the relationship to 
non-concentrated control but not absolute cell num-
bers. This is of particular importance as the frequency of 
these cells in the BM is very low, i.e. proximate to the flow 
cytometry detection limit. Despite this understanding, it is 
unclear if a greater presence of this subpopulation is rel-
evant for clinical efficacy, as others have shown that plate-
lets and trophic factors may also contribute to BMAC’s 
therapeutic effect.
Previous studies have illustrated that BMAC applica-
tion resulted in significant bone and cartilage healing in 
both animal models and human clinical trials [2, 3, 23]. 
In a recent review investigating the role of BMAC in ani-
mal long bone healing, 100% of the reviewed 35 manu-
scripts illustrated a significant increase in radiographic 
bone formation in the BMAC group, while 90% showed 
significant early bone healing on histological analysis and 
78% showed increased torsional stiffness when compared 
to controls [24]. In a prospective non-randomized human 
clinical trial, patients with large patellofemoral chondral 
lesions showed significantly improved clinical outcome 
scores at a minimum 3  year follow-up after treatment 
with autologous BMAC implanted into the chondral 
defect which was comparable to patients treated with 
matrix-induced autologous chondrocyte implantation 
[25]. In another study, patients with chondral lesions 
treated with BMAC plus a collagen scaffold experienced 
significant clinical improvement in all clinical scores 
compared to preoperative values, complete filling of the 
defect in 80% and hyaline like cartilage regeneration on 
histological analysis [26]. However, there is currently a 
lack of consensus for or against the use of a scaffold cou-
pled with BMAC for clinical applications [27].
Conclusion
Our data could contribute to the development of BMAC 
quality control assays as both commercial BMAC systems 
significantly concentrate MSC populations, platelets and 
growth factors, but not hematopoietic progenitor cells, 
compared to un-concentrated marrow aspirate. Clinical 
trials will be necessary to correlate specific MSC subpop-
ulations and growth factors with therapeutic efficacy.
Additional files
Additional file 1: Figure 1. Multicolor flow cytometry gating strategy 
to identify living cells (7-AAD negative), followed by identification of 
hematopoietic (CD45+) from non-hematopoietic (CD45−) cells with 
subsequent analysis (representative example). Note differences of viable 
CD45−CD73+CD90+ MSCs located in the upper right quadrants (aster-
isks) between BMAC and control.
Additional file 2: Table S1. Calculated percentages based on the event 
counts of viable cells analyzed by flow cytometry of both BMAC groups 
and controls.
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